Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity","authors":"Jeries Kort ,&nbsp;Nikolas Naleid ,&nbsp;Frank Oley ,&nbsp;James Ignatz-Hoover ,&nbsp;Seunghee Margevicius ,&nbsp;Pingfu Fu ,&nbsp;Ehsan Malek ,&nbsp;Brenda Cooper","doi":"10.1016/j.clml.2025.02.004","DOIUrl":"10.1016/j.clml.2025.02.004","url":null,"abstract":"<div><h3>Background</h3><div>Despite therapeutic advances, multiple myeloma (MM) remains challenging to treat effectively. High-dose melphalan (Mel200) with autologous stem cell transplantation (ASCT) is the standard treatment for transplant-eligible patients. Reduced-dose melphalan (Mel140) is an alternative for older or frail patients, yet its efficacy data remain unclear.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 233 MM patients undergoing first ASCT between 2014 and 2022, comparing outcomes between Mel140 (n = 82) and Mel200 (n = 151). We assessed patient demographics, disease characteristics, progression-free survival (PFS), and overall survival (OS). In an exploratory subset analysis achievement of MRD from bone marrow samples after ASCT was compared between the 2 groups.</div></div><div><h3>Results</h3><div>As expected, patients who received Mel 140 were significantly older with a higher KPS. Median follow-up was 47.7 months. Both groups had similar rates of readmissions and infections within the first 100 days after transplant despite Mel140 group being older with more comorbidities. No significant difference in PFS or OS was observed between Mel140 and Mel200 groups (<em>P</em> &gt; .05). MRD negativity rates at sensitivity levels of 10⁻⁵ and 10⁻⁶ were comparable (64% vs. 60%, <em>P</em> = .7). Patients achieving sustained MRD negativity demonstrated improved PFS regardless of melphalan dose.</div></div><div><h3>Conclusion</h3><div>Our findings suggest equivalent efficacy and safety profiles between Mel140 and Mel200, supporting Mel140 as a viable option for older or frail MM patients. In a subset analysis equivalent rates of MRD were achieved between the groups and remained a highly significant predictor of PFS, highlighting its relevance regardless of dosing strategies.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages e443-e451.e3"},"PeriodicalIF":2.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma","authors":"Fanyuan Zeng ,&nbsp;Hanwen Zhang ,&nbsp;Shuhua Wang ,&nbsp;Tenzin Passang ,&nbsp;Yiwen Li ,&nbsp;Christopher R. Funk ,&nbsp;Sarah Wyman ,&nbsp;Colin B. O'Leary ,&nbsp;Aseala I. Abousaud ,&nbsp;Yuan Liu ,&nbsp;Manali Rupji ,&nbsp;Kavita M. Dhodapkar ,&nbsp;Edmund K. Waller ,&nbsp;Jean L. Koff","doi":"10.1016/j.clml.2025.02.009","DOIUrl":"10.1016/j.clml.2025.02.009","url":null,"abstract":"<div><h3>Background</h3><div>Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for large B-cell lymphoma (LBCL); however, durable complete responses are achieved in only 30% to 40% of patients. Additionally, CAR-T therapy is frequently associated with significant toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).</div></div><div><h3>Patients and Methods</h3><div>We explored the translational potential of cytokines and chemokines as predictive biomarkers for CAR-T outcomes by analyzing 47 plasma cytokines/chemokines in serial blood samples from 24 LBCL patients undergoing CAR-T therapy. Blood samples were collected at multiple times: prelymphodepletion, day of CAR-T infusion (Day 0), and post-infusion. We investigated the association between cytokine levels and key clinical outcomes using machine learning models, including treatment response at 3 months, CRS, and ICANS.</div></div><div><h3>Results</h3><div>Higher day 0 IL-7, day 7 IL-21, and day 0 CCL8 levels correlated with improved remission rates. Conversely, elevated CRS risk was linked to higher day 0 CCL17 and day 3 CCL13, IL-6, and IFN-γ levels. ICANS development was associated with increased day 0 TGF-β1, and day 3 IL-5 and IL-7 levels, while lower day 0 CCL19 and day 3 VIP levels were inversely related to ICANS risk. Additionally, patients who received higher-intensity lymphodepletion had elevated day 0 CCL2 and IL-15 levels.</div></div><div><h3>Conclusion</h3><div>These findings highlight the role of plasma cytokines and chemokines as biomarkers for predicting both the therapeutic efficacy and toxicity of CART, with the potential to guide more personalized, safer, and effective immunotherapies for B cell lymphoma.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages e474-e486.e8"},"PeriodicalIF":2.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.","authors":"Katja Weisel, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, Hang Quach, Lee Bennett, Mihaela Talpes, Istvan Majer, Sachin Patel, Saad Z Usmani","doi":"10.1016/j.clml.2025.02.005","DOIUrl":"https://doi.org/10.1016/j.clml.2025.02.005","url":null,"abstract":"<p><strong>Background: </strong>In the phase 3 CANDOR trial (NCT03158688), daratumumab added to carfilzomib and dexamethasone (KdD) significantly prolonged progression-free survival relative to carfilzomib and dexamethasone (Kd) alone in previously treated patients with relapsed/refractory multiple myeloma (RRMM).</p><p><strong>Materials and methods: </strong>We present a post hoc analysis of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-item module (EORTC QLQ-C30) and EORTC QLQ Myeloma 20-item module (EORTC QLQ-MY20) patient-reported outcome (PRO) measures from the CANDOR trial.</p><p><strong>Results: </strong>Median (range) duration of observation for PROs was 18.4 (0.9-50.0) months (KdD) and 10.3 (0.9-48.4) months (Kd). PRO compliance rates were high and similar between arms. Mean scores on the EORTC QLQ-C30 global health status (GHS)/quality-of-life (QOL) scale were numerically higher in the KdD than in the Kd arm and were generally sustained or trended toward improvement from baseline. Other EORTC QLQ-C30, EORTC QLQ-MY20, and EQ-5D visual analog scale (VAS) scores were generally similar between treatment arms and were stable over time, with some numerical trends favoring KdD. Risks of deterioration were similar for most scales; hazard ratios suggested improvement for KdD for EORTC QLQ-C30 social functioning, EORTC QLQ-MY20 disease symptoms, and EQ-5D VAS. Results were consistent for lenalidomide-exposed and lenalidomide-refractory subgroups. EORTC QLQ-C30 GHS/QOL scores trended toward improvement at some time points, and other scores remained generally stable when daratumumab was added to carfilzomib and dexamethasone.</p><p><strong>Conclusion: </strong>These results support the benefits of KdD for the RRMM population, including lenalidomide-exposed and lenalidomide-refractory patients.</p><p><strong>Clinical trial registration: </strong>NCT03158688.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms","authors":"Joseph Cannova ,&nbsp;Shiv Shah ,&nbsp;Anand A. Patel","doi":"10.1016/j.clml.2025.02.003","DOIUrl":"10.1016/j.clml.2025.02.003","url":null,"abstract":"<div><div>Philadelphia-chromosome negative (Ph-neg) myeloproliferative neoplasms (MPNs) carry a variable rate of progression to the fibrotic stage of disease and/or the accelerated/blast-phase (AP/BP) of disease. Many of the challenging management scenarios that arise in the treatment of MPNs occur in those with higher-risk myelofibrosis (MF) or MPN-AP/BP. In this review we will focus upon 3 challenging clinical scenarios pertinent to the management of high-risk MPNs. We discuss how to incorporate molecular data into decision making around allogeneic hematopoietic stem cell transplantation in MF, strategies to address splenomegaly in patients with MF with inadequate response to an initial JAK inhibitor, and what sort of treatment approaches can be employed in the management of MPN-AP/BP.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 484-493"},"PeriodicalIF":2.7,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma","authors":"Wee Joo Chng ,&nbsp;David Bin-Chia Wu ,&nbsp;Cathy Kwang-Wei Wu ,&nbsp;Aaron Springford ,&nbsp;Caitlin H Daly ,&nbsp;Sung-Hoon Jung","doi":"10.1016/j.clml.2025.02.007","DOIUrl":"10.1016/j.clml.2025.02.007","url":null,"abstract":"<div><h3>Background</h3><div>Standard-of-care treatment for patients with multiple myeloma (MM) typically includes frontline lenalidomide until disease progression, making lenalidomide-refractoriness a challenge in relapsed/refractory MM (RRMM). Lenalidomide-sparing triplet therapies, daratumumab, pomalidomide, and dexamethasone (DPd) and pomalidomide, bortezomib, and dexamethasone (PVd), demonstrated efficacy in lenalidomide-exposed patients in the APOLLO and OPTIMISMM trials, respectively. Without head-to-head trial data, we assessed the comparative effectiveness of DPd versus PVd via matching-adjusted indirect comparison (MAIC).</div></div><div><h3>Materials and Methods</h3><div>Using APOLLO individual patient data (IPD) and OPTIMISMM aggregate covariate data plus pseudo-IPD for outcomes, the APOLLO population was re-weighted to match OPTIMISMM aggregate baseline characteristics. Bayesian posterior distributions of DPd versus PVd for progression-free survival (PFS) and overall survival (OS) were estimated using a likelihood-weighted Bayesian Cox model with fixed weights.</div></div><div><h3>Results</h3><div>At baseline, APOLLO included a higher proportion of patients who received ≥ 2 prior lines of therapy, were refractory to prior therapies, and had advanced International Staging System stage versus OPTIMISMM, which would otherwise disadvantage APOLLO versus OPTIMISMM. The PFS hazard ratio (HR) favored DPd over PVd at 0.59 (95% credible interval [CrI]: 0.36, 0.89) with 99% probability of DPd superiority versus PVd. The OS HR appeared to favor DPd over PVd at 0.80 (95% CrI: 0.45, 1.30), with 83% probability of DPd superiority versus PVd; however, the estimated OS benefit was not conclusive.</div></div><div><h3>Conclusion</h3><div>This analysis suggests that DPd improves PFS and might improve OS versus PVd in patients with RRMM. Additional evidence from head-to-head trials or real-world patient databases are warranted to confirm these results.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages e457-e465"},"PeriodicalIF":2.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody Response to Pneumococcal, Influenza, and COVID-19 Vaccination in Patients With Multiple Myeloma","authors":"Pranjal Singh ,&nbsp;Charanpreet Singh ,&nbsp;Kamaljeet Kamaljeet ,&nbsp;Vijayalakshmi Aravindan Arun ,&nbsp;Radha Kanta Ratho ,&nbsp;Archana Angrup ,&nbsp;Arihant Jain ,&nbsp;Sreejesh Sreedharanunni ,&nbsp;Gaurav Prakash ,&nbsp;Alka Khadwal ,&nbsp;Pankaj Malhotra","doi":"10.1016/j.clml.2025.02.006","DOIUrl":"10.1016/j.clml.2025.02.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Vaccination for common pathogens implicated in causing respiratory illness in patients with Multiple Myeloma (MM) is now recommended by most experts. However, there is limited data regarding the effectiveness of vaccination in these patients.</div></div><div><h3>Methods</h3><div>We conducted a prospective study on the efficacy of pneumococcal, influenza, and COVID-19 vaccination in patients with newly diagnosed MM treated at our center between January and June 2021.</div></div><div><h3>Results</h3><div>Thirty patients completed the vaccination and were analyzed for the effectiveness of the vaccines. A significant rise in pneumococcal (2.87 U/ml vs. 0.68 U/ml; <em>P</em> &lt; .001), Influenza (0.25 IU/L vs. 0.08 IU/L; <em>P</em> &lt; 0.001) and COVID-19 (3.86 IU/L vs. 0.24 IU/L; <em>P</em> &lt; .001) antibody titres was seen in our patients. Nineteen patients (63.3%), 16 patients (53.3%), and 16 patients (53.3%) achieved seroconversion for pneumococcus, influenza, and COVID-19 postvaccination, respectively, and exhibited a 4-fold rise in antibody titer. No serious adverse events were reported after vaccination in the cohort. During the 6-month follow-up, ten patients developed respiratory tract infections- 4 with lower respiratory tract and 6 with upper respiratory tract infections. None of the patients had infections attributable to pneumococcus, influenza, or COVID-19.</div></div><div><h3>Conclusion</h3><div>Our study showed a 50% to 60% seroconversion after vaccination against 3 common respiratory pathogens in patients with newly diagnosed MM.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 527-531"},"PeriodicalIF":2.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Pharmacokinetics and Efficacy of Generic Melphalan is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation” [Clin Lymphoma Myeloma Leuk. 20/2 (2020) 130-135.e1]","authors":"","doi":"10.1016/j.clml.2025.01.015","DOIUrl":"10.1016/j.clml.2025.01.015","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 5","pages":"Page 379"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions","authors":"Vishrut Shah,&nbsp;Farhad Ravandi","doi":"10.1016/j.clml.2025.02.001","DOIUrl":"10.1016/j.clml.2025.02.001","url":null,"abstract":"<div><div>Advances in understanding leukemogenesis in acute myeloid leukemia (AML) have led to new drug approvals in the past 4 years. Ongoing preclinical research is expected to produce more targeted therapies, reducing the need for traditional chemotherapy, while also enhancing classification systems and patient prognostication. In newly diagnosed AML, the mainstay of induction still is 7+3 regimen. In unfit adults, combination of venetoclax and hypomethylating agent has emerged to be the standard of care. Introduction of FLT3 inhibitors with the 7 plus 3 regimen has improved outcomes in FLT3 mutant patients. IDH inhibitors have recently been approved for induction in medically unfit adult. Studies focusing on triplet regimen are underway. FLT3 inhibitors and IDH inhibitors have also been approved for Relapsed and Refractory AML. Menin inhibitors are another novel class of drugs which are currently being studied for both de novo as well as relapsed and refractory AML. For consolidation in fit patients, high dose cytarabine and Allogenic transplant are still the mainstay of treatment whenever feasible. FLT3 inhibitors have been studied as long term maintenance after allogenic stem cell transplantation. As potent regimens achieve high-quality remissions, the need for sensitive assays to detect measurable residual disease (MRD) and predict relapse risk will grow. MRD monitoring using flow cytometry and molecular methods have been effective with cytarabine-based treatments and will be crucial for venetoclax therapies. Eradicating MRD is a key goal for AML subsets, with research focused on targeted and immune- based therapies to eliminate MRD and understand relapse through clonal evolution. Allogeneic stem cell transplant is the most effective treatment for residual leukemia in resistant AML but is limited by toxicity and donor availability. Immune-based strategies, including antibodies and bispecific molecules, show promise in early trials, and safer cellular therapies could expand treatment options.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 465-475"},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma","authors":"Maria Cristina Pirosa ,&nbsp;Anastasios Stathis ,&nbsp;Davide Rossi ,&nbsp;Emanuele Zucca","doi":"10.1016/j.clml.2025.02.002","DOIUrl":"10.1016/j.clml.2025.02.002","url":null,"abstract":"<div><div>Current classifications identify 3 primary types of marginal zone lymphoma (MZL): extra nodal, splenic, and nodal MZL. MZLs typically have excellent long-term outcomes and often do not require immediate treatment. For asymptomatic patients, active surveillance (watch-and-wait) is the standard approach. However, exceptions exist. Asymptomatic patients with Helicobacter pylori-positive gastric MZL should receive antibiotic eradication therapy upon diagnosis. Similarly, asymptomatic patients infected with hepatitis C virus (HCV) should receive antiviral therapy. Surgical resection is generally not indicated. Involved-site radiotherapy (ISRT) is recommended for localized disease (20-24Gy, depending on the anatomical site). While higher doses are often needed for curative intent, very low-dose ISRT (2×2 Gy) can achieve long-term control and provide effective palliation with minimal toxicity when a definitive cure is not the goal. Symptomatic patients with advanced-stage disease may benefit from systemic rituximab-based treatment. Rituximab monotherapy is suitable for patients who cannot tolerate chemotherapy or prioritize a low-toxicity initial approach. The combination of rituximab with bendamustine or chlorambucil can result in longer response duration and progression-free survival, but not in improved overall survival, and may be preferred for severely symptomatic patients with advanced disease. More intensive doxorubicin-containing regimens, which are more toxic, should be reserved for patients with histological transformation, aggressive presentations, or bulky masses. Although data from clinical trials are limited, several new therapies have shown encouraging results, including bispecific antibodies, chimeric antigen receptor (CAR)-T cell therapy, and small molecules. Treatment choices depend on the MZL subtype, stage, age, comorbidities, and therapeutic goals.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 476-483"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience","authors":"Omar Elghawy ,&nbsp;Julia Wang ,&nbsp;Olivia J. Leung ,&nbsp;Nishwant Swami ,&nbsp;Veronica Carvajal ,&nbsp;Guang Yang ,&nbsp;Daniel J. Landsburg ,&nbsp;Jakub Svoboda ,&nbsp;Sunita D. Nasta ,&nbsp;Elise A. Chong ,&nbsp;Stephen J. Schuster ,&nbsp;Colin J. Thomas ,&nbsp;Jordan S. Carter ,&nbsp;Adam Bagg ,&nbsp;Stefan K. Barta","doi":"10.1016/j.clml.2025.01.017","DOIUrl":"10.1016/j.clml.2025.01.017","url":null,"abstract":"<div><h3>Background</h3><div>The understanding of T-cell lymphoma (TCL) pathobiology has grown substantially due to gene expression profiling and high-throughput next-generation sequencing (NGS). However, real-world data on mutational profiles of mature T-cell lymphomas (TCLs) are limited, and their impact on clinical decision making has not been reported.</div></div><div><h3>Methods</h3><div>A single-institution study of biopsies from patients with histopathologically confirmed T-cell lymphomas and available NGS data between January 1, 2021, to July 1, 2023, was performed. Reported variants were classified as disease-associated or pathogenic variants (DAV), or variants of unknown significance (VUS). Individual physicians were surveyed via email regarding the impact of NGS results on next steps in patient care.</div></div><div><h3>Results</h3><div>About 94% of patients (<em>n</em> = 93) had ≥ 1 variants identified; at least 1 pathogenic variant or likely pathogenic variant was identified in 71% of patients (<em>n</em> = 70). Variants were detected in 90 unique genes with 41% (37/90) having disease-associated variants (DAV). The genes with mutations most frequently resulting in disease-associated variants in this study were <em>TET2, RHOA, DNMT3A</em> and <em>TP53, IDH2,</em> and <em>PLCG1.</em> NGS results were integral to clinical management in 19% of patients per physician survey.</div></div><div><h3>Conclusion</h3><div>This work gives insight into the real-world utility of NGS regarding clinical decision making for patients with T-cell lymphoma. Given the impact of NGS on prognostication, evaluation of therapeutic options, as well as cessation of potentially unhelpful treatments, these findings support the role of NGS as an important part in the management of T-cell lymphomas.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 505-511.e2"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}